
Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company developing cell therapies for patients suffering from autoimmune diseases. Guided by our core values, Stay True to Why, Collaborate to Accelerate, Lead with Clarity, Boldly Innovative, and Own the Outcome, we are committed to transforming the future of treatment for autoimmune disease. Join us at the forefront of cell therapy innovation and help redefine what’s possible.
Title Senior Director, Corporate Communications
Location Emeryville, CA (Hybrid) or Remote eligible
Reports to SVP, Head of Corporate Affairs
The Senior Director, Corporate Communications will serve as a corporate affairs generalist, partnering closely with business leaders to position Kyverna as a leader in the autoimmune CAR T field, while engaging employees internally to drive business results. This leader will be responsible for overseeing the Company’s corporate and pipeline communications with a particular emphasis on its lead program in stiff person syndrome. The role will also shape and execute the Company’s social media strategy, elevate its corporate profile, and drive impactful internal communications programming.
Corporate & Pipeline Communications:
Internal Communications:
Requirements:
The national salary range for this position is $240,000 to $270,000 USD annually. This salary range is an estimate of what we reasonably expect to pay for this position, and the actual salary may vary based on various factors, including without limitation individual education, experience, tenure, skills and abilities, as well as internal equity and alignment with market data. This position is also eligible for bonus, benefits, and participation in Company’s stock plan.

Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis.
Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.